Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.70 |
| ▸ | CA2 | P00918 | 4/20 | 0.70 |
| ▸ | ACHE | P22303 | 3/20 | 0.70 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337809 | 1.00 | CA1 (0.70) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL17335544 | 0.89 | CA1 (0.64) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3975748 | 0.85 | MTNR1A (0.90) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL5783028 | 0.85 | CA1 (0.67) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL7352131 | 0.82 | CA1 (0.70) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3854031 | 0.80 | MTNR1A (1.00) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL11493562 | 0.80 | DRD2 (0.71) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL11008652 | 0.80 | ACHE (0.62) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL2597383 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL827706 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0781126-B1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON SPA (IT) | 2001-12-12 | — | — | EP | disclosed |
| EP-0781126-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.p.A. (IT) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008228-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.P.A. (IT) | 1996-03-21 | — | — | WO | disclosed |
| US-4442126-A | PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS | SYNTHELABO (FR) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | CA1 3139/4885CA2 3174/4885ACHE 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.